Yuval Itan, PhD
img_Yuval Itan
ASSOCIATE PROFESSOR | Genetics and Genomic Sciences
Research Topics
Bioinformatics, Biomedical Informatics, Biomedical Sciences, Biostatistics, Cardiovascular, Clinical Genomics, Computational Biology, Computer Simulation, Coronavirus, Epidemiology, Evolution, Gastroenterology, Gene Discovery, Genetics, Genomics, Immune Deficiency, Infectious Disease, Inflammatory Bowel Disease (IBD), Mathematical Modeling of Biomedical Systems, Mathematical and Computational Biology, Neural Networks, Obesity, Parkinson's Disease, Personalized Medicine, Proteomics, Sequence Alignment, Systems Biology, Technology & Innovation, Theoretical Biology, Translational Research
Multi-Disciplinary Training Area
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Genetics and Genomic Sciences [GGS]
Investigating population-specific disease-causing mutations, genes and pathways
Different human populations display varying genomic architectures, that are likely to result in population-specific disease-causing mutations, genes and pathways. We currently investigate this concept with Ashkenazi Jewish (AJ) inflammatory bowel disease (IBD) patients from the IBD genetics consortium (IBDGC) whole exome sequencing data, that we identify by admixture and principal component analyses (PCA). We perform a gene burden analysis of cases vs controls, focusing on high-impact rare genetic variants. We use PheWAS to further validate our results. We aim to then extend the analysis to other human populations (Hispanic, African American and European) for identifying population-specific IBD genomic signals.

Itan lab webpage
Deep neural network predictions of pathogenic mutations
While there has been an extensive effort in identifying pathogenic mutations in patients’ genomes, current methods still cannot efficiently prioritize the true pathogenic mutations in patients. We showed that by using extensive annotations it is possible to cluster mutations by disease groups. We aim to deep neural network (aka “deep learning”) classifier to efficiently and automatically prioritize pathogenic mutations in patients’ genomes, by considering the disease of the patient, train based on extensive annotations at the variant-, gene- and pathway-levels, and separate the training sets by disease groups and high-quality non-trivial neutral genetic variants.
Predicting the functional consequence of mutations
Gain-of-function (GOF) and loss-of-function (LOF) mutations in the same gene result in different diseases and require different treatment. We aim to develop the first computational method to efficiently predict if a mutation is GOF, LOF or neutral by: (1) creating the first extensive GOF and LOF database by extracting data with natural language processing (NLP) algorithm on abstracts of known pathogenic mutations; (2) applying statistical and feature selection approach to detect protein-level and gene-level features that best differentiate GOF from LOF and neutral mutations; and (3) developing a Random Forest classifier and a public server to predict the functional consequence of mutations. We use Phenome-Wide Associations (PheWAS) on Mount Sinai’s BioMe resource for validating our resource and detect novel GOF/LOF phenotypes.

BSc, Bar-Ilan University

PhD, University College London

Postdoc, The Rockefeller University

Publications

Selected Publications

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome Medicine, (2023), 15, 1, (22), 10.1186/s13073-023-01173-8). Daniela Matuozzo, Estelle Talouarn, Astrid Marchal, Peng Zhang, Jeremy Manry, Yoann Seeleuthner, Yu Zhang, Alexandre Bolze, Matthieu Chaldebas, Baptiste Milisavljevic, Adrian Gervais, Paul Bastard, Takaki Asano, Lucy Bizien, Federica Barzaghi, Hassan Abolhassani, Ahmad Abou Tayoun, Alessandro Aiuti, Ilad Alavi Darazam, Luis M. Allende, Rebeca Alonso-Arias, Andrés Augusto Arias, Gokhan Aytekin, Peter Bergman, Simone Bondesan, Yenan T. Bryceson, Ingrid G. Bustos, Oscar Cabrera-Marante, Sheila Carcel, Paola Carrera, Giorgio Casari, Khalil Chaïbi, Roger Colobran, Antonio Condino-Neto, Laura E. Covill, Ottavia M. Delmonte, Loubna El Zein, Carlos Flores, Peter K. Gregersen, Marta Gut, Filomeen Haerynck, Rabih Halwani, Selda Hancerli, Lennart Hammarström, Nevin Hatipoğlu, Adem Karbuz, Sevgi Keles, Dusan Bogunovic, Yuval Itan, Nadjib Hammoudi. Genome Medicine

The landscape of rare genetic variation associated with inflammatory bowel disease and Parkinson’s disease comorbidity. Meltem Ece Kars, Yiming Wu, Peter D. Stenson, David N. Cooper, Johan Burisch, Inga Peter, Yuval Itan. Genome Medicine

Inherited human RelB deficiency impairs innate and adaptive immunity to infection. Tom Le Voyer, Majistor Raj Luxman Maglorius Renkilaraj, Kunihiko Moriya, Malena Pérez Lorenzo, Tina Nguyen, Liwei Gao, Tamar Rubin, Axel Cederholm, Masato Ogishi, Carlos A. Arango-Franco, Vivien Béziat, Romain Lévy, Mélanie Migaud, Franck Rapaport, Yuval Itan, Elissa K. Deenick, Irene Cortese, Andrea Lisco, Kaan Boztug, Laurent Abel, Stéphanie Boisson-Dupuis, Bertrand Boisson, Patrick Frosk, Cindy S. Ma, Nils Landegren, Fatih Celmeli, Jean Laurent Casanova, Stuart G. Tangye, Anne Puel. Proceedings of the National Academy of Sciences of the United States of America

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Itan has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.